For
decades, titanium and its alloys have been established as a
biocompatible material for cardiovascular medical devices such as
heart valves, stents, vascular grafts, catheters, etc. However, thrombosis
is one of the reasons for implant failure, where blood clot forms
on the implant surface, thus obstructing the flow of the blood and
that leads to some serious complications. Various surface modification
techniques such as heparin modification, albumin coating, surface
anodization, plasma etching, and hydrothermal treatments have been
explored to improve the hemocompatibility of titanium-based materials.
However, there are several limitations related to the robustness of
the surfaces and long-term efficacy in vivo. In this study, titanium
and its alloy Ti–6Al–4V were hydrothermally treated
to form nanostructured surfaces with the aim to enhance their hemocompatibility.
These modified surfaces were characterized for their wettability,
surface morphology, surface chemistry, and crystallinity. The hemocompatibility
of these surfaces was characterized by evaluating blood plasma protein
adsorption, platelet adhesion and activation, platelet–leukocyte
complex formation, and whole blood clotting. The results indicate
lower fibrinogen adsorption, cell adhesion, platelet activation, and
whole blood clotting on hydrothermally treated surfaces. Thus, these
surfaces may be a promising approach to prevent thrombosis for several
titanium blood-contacting medical devices.